This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

A research team has uncovered a previously unknown type of immune signaling molecule—a novel compound combining histidine and ...

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

What to gift for Mother's Day? Though cards, chocolate, and flower arrangements are cherished traditions, they fall short in ...

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical ...

A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

The process the immortal jellyfish uses to cheat death is like a form of cloning. If we can adapt it to the human body, it ...

BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based ...